ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-0Z7790
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Insights, Forecast to 2030

Code: QYRE-Auto-0Z7790
Report
December 2024
Pages:110
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Alexion Pharmaceuticals Inc
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd
Sagent Pharmaceuticals, Inc
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune
RemeGen, Ltd.

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market

Devic’s Syndrome (Neuromyelitis Optica) Treatment Market

Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.
Market Analysis and Insights: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Devic’s Syndrome (Neuromyelitis Optica) Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Devic’s Syndrome (Neuromyelitis Optica) Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Devic’s Syndrome (Neuromyelitis Optica) Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Devic’s Syndrome (Neuromyelitis Optica) Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Devic’s Syndrome (Neuromyelitis Optica) Treatment revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Report

Report Metric Details
Report Name Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospitals
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Alkem Laboratories Ltd., Mylan Pharmaceuticals, Inc., Hoffmann-La Roche/ Chugai Pharmaceutical, MedImmune LLC, RemeGen, Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Devic’s Syndrome (Neuromyelitis Optica) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Devic’s Syndrome (Neuromyelitis Optica) Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Devic’s Syndrome (Neuromyelitis Optica) Treatment revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report?

Ans: The main players in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Alkem Laboratories Ltd., Mylan Pharmaceuticals, Inc., Hoffmann-La Roche/ Chugai Pharmaceutical, MedImmune LLC, RemeGen, Ltd.

What are the Application segmentation covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report?

Ans: The Applications covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report are Hospitals, Clinic, Others

What are the Type segmentation covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report?

Ans: The Types covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report are Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab

Recommended Reports

Neurological Disorders

Rare Syndrome Treatments

Eye and Nerve Disorders

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Eculizumab
1.2.3 Methylprednisolone
1.2.4 Azathioprine
1.2.5 Mycophenolate Mofetil
1.2.6 Rituximab
1.3 Market by Application
1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2019-2030)
2.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Region
2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Dynamics
2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Trends
2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Devic’s Syndrome (Neuromyelitis Optica) Treatment by Players
3.1.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2019-2024)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2023
3.5 Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment Head office and Area Served
3.6 Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, Product and Application
3.7 Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2025-2030)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
6.2.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024)
6.2.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030)
6.2.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
6.3.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024)
6.3.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030)
6.3.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
6.4.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
6.4.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
7.2.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024)
7.2.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030)
7.2.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
7.3.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024)
7.3.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030)
7.3.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
7.4.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
7.4.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
8.2 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
8.2.1 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024)
8.2.2 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030)
8.2.3 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
8.3 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
8.3.1 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024)
8.3.2 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030)
8.3.3 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
9.2 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
9.2.1 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024)
9.2.2 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030)
9.2.3 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
9.3 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
9.3.1 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024)
9.3.2 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030)
9.3.3 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
9.4 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
9.4.1 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024)
9.4.3 Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Alexion Pharmaceuticals, Inc.
11.1.1 Alexion Pharmaceuticals, Inc. Company Details
11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.1.5 Alexion Pharmaceuticals, Inc. Recent Developments
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.2.5 Teva Pharmaceuticals Recent Developments
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Company Details
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.3.5 Fresenius Kabi AG Recent Developments
11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments
11.5 Lupin Ltd.
11.5.1 Lupin Ltd. Company Details
11.5.2 Lupin Ltd. Business Overview
11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.5.5 Lupin Ltd. Recent Developments
11.6 Sagent Pharmaceuticals, Inc.
11.6.1 Sagent Pharmaceuticals, Inc. Company Details
11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.6.5 Sagent Pharmaceuticals, Inc. Recent Developments
11.7 Zydus Pharmaceuticals, Inc.
11.7.1 Zydus Pharmaceuticals, Inc. Company Details
11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.7.5 Zydus Pharmaceuticals, Inc. Recent Developments
11.8 Sandoz Inc. (Novartis)
11.8.1 Sandoz Inc. (Novartis) Company Details
11.8.2 Sandoz Inc. (Novartis) Business Overview
11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.8.5 Sandoz Inc. (Novartis) Recent Developments
11.9 Alkem Laboratories Ltd.
11.9.1 Alkem Laboratories Ltd. Company Details
11.9.2 Alkem Laboratories Ltd. Business Overview
11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.9.5 Alkem Laboratories Ltd. Recent Developments
11.10 Mylan Pharmaceuticals, Inc.
11.10.1 Mylan Pharmaceuticals, Inc. Company Details
11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.10.5 Mylan Pharmaceuticals, Inc. Recent Developments
11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments
11.12 MedImmune LLC
11.12.1 MedImmune LLC Company Details
11.12.2 MedImmune LLC Business Overview
11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.12.5 MedImmune LLC Recent Developments
11.13 RemeGen, Ltd.
11.13.1 RemeGen, Ltd. Company Details
11.13.2 RemeGen, Ltd. Business Overview
11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
11.13.5 RemeGen, Ltd. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Alexion Pharmaceuticals Inc
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd
Sagent Pharmaceuticals, Inc
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune
RemeGen, Ltd.
List of Tables
    Table 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Eculizumab
    Table 3. Key Players of Methylprednisolone
    Table 4. Key Players of Azathioprine
    Table 5. Key Players of Mycophenolate Mofetil
    Table 6. Key Players of Rituximab
    Table 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2019-2024)
    Table 11. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2025-2030)
    Table 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
    Table 14. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
    Table 15. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
    Table 16. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
    Table 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Players (2019-2024)
    Table 19. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2023)
    Table 20. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Ranking 2022 VS 2023 VS 2024
    Table 21. Global 5 Largest Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, Headquarters and Area Served
    Table 23. Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, Product and Application
    Table 24. Global Key Players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, Product and Application
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2019-2024)
    Table 28. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2025-2030)
    Table 30. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Application (2019-2024)
    Table 32. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Application (2025-2030)
    Table 34. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 35. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 36. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 37. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 38. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 39. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 40. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 41. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 42. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 43. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 44. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 45. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 48. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 49. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 50. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 51. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 52. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 53. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 54. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 55. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 56. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 57. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 58. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 64. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 66. Alexion Pharmaceuticals, Inc. Company Details
    Table 67. Alexion Pharmaceuticals, Inc. Business Overview
    Table 68. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 69. Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 70. Alexion Pharmaceuticals, Inc. Recent Developments
    Table 71. Teva Pharmaceuticals Company Details
    Table 72. Teva Pharmaceuticals Business Overview
    Table 73. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 74. Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 75. Teva Pharmaceuticals Recent Developments
    Table 76. Fresenius Kabi AG Company Details
    Table 77. Fresenius Kabi AG Business Overview
    Table 78. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 79. Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 80. Fresenius Kabi AG Recent Developments
    Table 81. Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
    Table 82. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
    Table 83. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 84. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 85. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments
    Table 86. Lupin Ltd. Company Details
    Table 87. Lupin Ltd. Business Overview
    Table 88. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 89. Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 90. Lupin Ltd. Recent Developments
    Table 91. Sagent Pharmaceuticals, Inc. Company Details
    Table 92. Sagent Pharmaceuticals, Inc. Business Overview
    Table 93. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 94. Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 95. Sagent Pharmaceuticals, Inc. Recent Developments
    Table 96. Zydus Pharmaceuticals, Inc. Company Details
    Table 97. Zydus Pharmaceuticals, Inc. Business Overview
    Table 98. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 99. Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 100. Zydus Pharmaceuticals, Inc. Recent Developments
    Table 101. Sandoz Inc. (Novartis) Company Details
    Table 102. Sandoz Inc. (Novartis) Business Overview
    Table 103. Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 104. Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 105. Sandoz Inc. (Novartis) Recent Developments
    Table 106. Alkem Laboratories Ltd. Company Details
    Table 107. Alkem Laboratories Ltd. Business Overview
    Table 108. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 109. Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 110. Alkem Laboratories Ltd. Recent Developments
    Table 111. Mylan Pharmaceuticals, Inc. Company Details
    Table 112. Mylan Pharmaceuticals, Inc. Business Overview
    Table 113. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 114. Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 115. Mylan Pharmaceuticals, Inc. Recent Developments
    Table 116. Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
    Table 117. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
    Table 118. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 119. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 120. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments
    Table 121. MedImmune LLC Company Details
    Table 122. MedImmune LLC Business Overview
    Table 123. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 124. MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 125. MedImmune LLC Recent Developments
    Table 126. RemeGen, Ltd. Company Details
    Table 127. RemeGen, Ltd. Business Overview
    Table 128. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 129. RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)
    Table 130. RemeGen, Ltd. Recent Developments
    Table 131. Research Programs/Design for This Report
    Table 132. Key Data Information from Secondary Sources
    Table 133. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2023 VS 2030
    Figure 3. Eculizumab Features
    Figure 4. Methylprednisolone Features
    Figure 5. Azathioprine Features
    Figure 6. Mycophenolate Mofetil Features
    Figure 7. Rituximab Features
    Figure 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2023 VS 2030
    Figure 10. Hospitals Case Studies
    Figure 11. Clinic Case Studies
    Figure 12. Others Case Studies
    Figure 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
    Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region: 2023 VS 2030
    Figure 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2023
    Figure 18. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2023
    Figure 20. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
    Figure 22. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
    Figure 23. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)
    Figure 24. United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 27. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
    Figure 28. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
    Figure 29. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)
    Figure 30. Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. France Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. U.K. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Nordic Countries Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
    Figure 38. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
    Figure 39. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
    Figure 41. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
    Figure 42. Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2019-2030)
    Figure 43. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. China Taiwan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)
    Figure 53. Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Israel Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. GCC Countries Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 60. Teva Pharmaceuticals Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 61. Fresenius Kabi AG Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 62. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 63. Lupin Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 64. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 65. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 66. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 67. Alkem Laboratories Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 68. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 69. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 70. MedImmune LLC Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 71. RemeGen, Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Neuromyelitis Optica Spectrum Disorders NMOSD Market Research Report 2024
Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Research Report 2024
Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Optic Nerve Disorders Treatment Market Insights Forecast to 2030
Neuromyelitis Optica Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Global Neuromyelitis Optica Drug Market Research Report 2025
Drugs for Neuromyelitis Optica Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Sclerosis Drugs Treatment Market Insights Forecast to 2030
Neuromyelitis Optic Spectrum Disorder Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Open Angle Glaucoma Therapeutics Market Insights Forecast to 2030
Global Spinal Cord Trauma Treatment Market Insights Forecast to 2030
Transverse Myelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030
Global Chronic Fatigue Syndrome Treatment Market Insights Forecast to 2030
Transverse Myelitis Diagonosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Guillain Barre Syndrome Treatment Market Research Report 2025
Global Optic Neuritis Drug Market Research Report 2025
Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Duane Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions